🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Shanghai Vitalgen BioPharma clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Shanghai Vitalgen BioPharma as lead sponsor. Synced 26 Sep 2026
7Current trials
1Recruiting now
2Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Shanghai Vitalgen BioPharma is the lead sponsor of 7 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are VGR-R01 and VGN-R09b. The most-studied condition is Bietti Crystalline Dystrophy.

ClinicalTrials.gov trials by status

  • Recruiting114%
  • Not yet open229%
  • Active, closed457%

Trials by phase

  • Phase 1/2343%
  • Phase 1229%
  • Phase 3114%
  • Phase 2/3114%
01

Clinical trials sponsored by Shanghai Vitalgen BioPharma

7 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b
NCT06217861 · ClinicalTrials.gov ↗ · Glutaric Acidemia Type I, Glutaric Aciduria Type I
Phase 1 Recruiting 2024-04 China
A Safety Study of Contralateral Eye Dosing of VGR-R01 in Participants With Bietti's Crystalline Dystrophy (BCD)
NCT07586306 · ClinicalTrials.gov ↗ · Bietti Crystalline Dystrophy
Drug: VGR-R01
Phase 1/2 Not yet open 2026-06 China
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations
NCT07414290 · ClinicalTrials.gov ↗ · Parkinson Disease (PD)
Phase 1/2 Not yet open 2026-05 China
Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy
NCT06699108 · ClinicalTrials.gov ↗ · Bietti Crystalline Dystrophy, Inherited Retinal Diseases
Drug: VGR-R01
Phase 3 Active, closed 2024-12 China
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency
NCT06432140 · ClinicalTrials.gov ↗ · Aromatic L-amino Acid Decarboxylase Deficiency
Phase 2/3 Active, closed 2024-07 China
Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy
NCT05694598 · ClinicalTrials.gov ↗ · Bietti Crystalline Dystrophy
Phase 1 Active, closed 2023-03 China
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease
NCT06480461 · ClinicalTrials.gov ↗ · Parkinson's Disease
Drug: VGN-R09b
Phase 1/2 Active, closed 2024-09 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Shanghai Vitalgen BioPharma trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Shanghai Vitalgen BioPharma trials

7 conditions
Bietti Crystalline Dystrophy3Inherited Retinal Diseases1Aromatic L-amino Acid Decarboxylase Deficiency1Parkinson's Disease1Parkinson Disease (PD)1Glutaric Acidemia Type I1Glutaric Aciduria Type I1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China71

A trial with sites in more than one country appears in each of those registers.

05

Questions about Shanghai Vitalgen BioPharma trials

How many clinical trials does Shanghai Vitalgen BioPharma sponsor?

Shanghai Vitalgen BioPharma is the lead sponsor of 7 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Shanghai Vitalgen BioPharma trials recruiting?

Yes. 1 of its 7 ClinicalTrials.gov trials is recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shanghai Vitalgen BioPharma testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are VGR-R01 (2) and VGN-R09b (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.